1. Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment
   Gabriela R. Passos et al, 2018, Med Oncol CrossRef
2. How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive
   Alessandro Poggi et al, 2018, Front. Immunol. CrossRef
3. Old wine in new bottles: Drug repurposing in oncology
   Michał Antoszczak et al, 2019, European Journal of Pharmacology CrossRef
4. Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis
   De-Dong Cao et al, 2017, Oncotarget CrossRef
5. Overexpression of ubiquitin specific proteases 44 promotes the malignancy of glioma by stabilizing tumor-promoter securin
   Yongxiang Zou et al, 2017, Oncotarget CrossRef
6. Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients
   Yuanyuan Sun et al, 2020, Ther Adv Med Oncol CrossRef
7. Overcoming cancer therapeutic bottleneck by drug repurposing
   Zhe Zhang et al, 2020, Sig Transduct Target Ther CrossRef
8. Effects of thalidomide on growth and VEGF-A expression in SW480 colon cancer cells
   Xin Zhang et al, 2017, Oncol Lett CrossRef
9. Expression and function of Toll‑like receptors in peripheral blood mononuclear cells in patients with ankylosing spondylitis
   Jun Zhang et al, 2019, Mol Med Report CrossRef
10. A Novel Nanoemulsion Formula for an Improved Delivery of a Thalidomide Analogue to Triple-Negative Breast Cancer; Synthesis, Formulation, Characterization and Molecular Studies
    Noran M Tawfik et al, 2023, IJN CrossRef
11. Thalidomide suppresses migration and invasion of colorectal cancer cells by inhibiting HOXB7‐mediated activation of the Wnt/β‐catenin signaling pathway
    Liyang Liu et al, 2024, Chem Biol Drug Des CrossRef
12. The Role of Hypoxia-inducible Factor-1 in Bladder Cancer
    Jiagui Chai et al, 2024, CMM CrossRef